cholecystokinin 2 receptor targeting

You have access
Cholecystokinin 2 Receptor Agonist ¹⁷⁷Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study
Christof Rottenburger, Guillaume P. Nicolas, Lisa McDougall, Felix Kaul, Michal Cachovan, A. Hans Vija, Roger Schibli, Susanne Geistlich, Anne Schumann, Tilman Rau, Katharina Glatz, Martin Behe, Emanuel R. Christ and Damian Wild

Journal of Nuclear Medicine April 1, 2020, 61 (4) 520-526; DOI: https://doi.org/10.2967/jnumed.119.233031

Main menu